US EditionTransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
- TransCode convened its Special Meeting on April 21, 2025, and then adjourned it to May 2, 2025.
- TransCode adjourned the meeting because a quorum, the required number of shares represented, was not present.
- The reconvened meeting will occur virtually on May 2, 2025, at 9:30 a.m. Eastern Time, accessible via a specific website.
- Proxies representing about 12.73% of the outstanding shares had been submitted before adjournment; TransCode urges voting.
- TransCode encourages stockholders to vote on Proposals One and Two by May 1, 2025; after that, votes can only be cast during the meeting.
Insights by Ground AI
Does this summary seem wrong?
34 Articles
34 Articles
All
Left
Center
11
Right
1
Farm Talk Newspaper+33 Reposted by 33 other sources
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
BOSTON, April 21, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on April 21,…
·Parsons, United States
Read Full ArticleCoverage Details
Total News Sources34
Leaning Left0Leaning Right1Center11Last UpdatedBias Distribution92% Center
Bias Distribution
- 92% of the sources are Center
92% Center
C 92%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
